Suchen und filtern

Gefundene Studien

R-BRAVE R-BRAVE (Rare BRAF Variant Registry Germany): Multizentrische, retrospektive Erhebung von Patienten-Verläufen mit BRAF Non-V600-mutierten soliden Tumoren AIO-TF/YMO-0223 · In Rekrutierung Studie anzeigen

HCQ/MEKi/CDK4/6i–PDAC MEK-Inhibition in Kombination mit Hydroxychloroquin bzw. CDK4/6-Inhibition beim Pankreaskarzinom: eine retrospektive Fallsammlung AIO-TF/PAK-0123 · Studie beendet Studie anzeigen

RECONVERT Interval chemotherapy for colorectal cancer patients undergoing multimodal two-stage hepatectomy for bilobar liver metastases AIO-KRK/YMO-0123 · In Vorbereitung Studie anzeigen

GENDER-CRC (FIRE-11) Single-Agent Versus Combination Chemotherapy Plus Targeted Therapy in Female Patients With Metastatic Colorectal Cancer: A Randomized Non-Inferiority Study (FIRE-11) AIO-KRK-0223 · In Vorbereitung Studie anzeigen

PACE-LUNG Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment AIO-TRK-0422/ass · In Rekrutierung Studie anzeigen

HEAT Head and Neck Carcinoma Clinical Research Platform for molecular and blood-based biomarkers, treatment and outcome AIO-KHT-0322/ass · In Rekrutierung Studie anzeigen

ALPINE A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung AIO-TRK-0322 · In Rekrutierung Studie anzeigen

ANTELOPE Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma AIO-TRK-0122 · In Rekrutierung Studie anzeigen

MINERVA Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management AIO-MAM-0122/ass · In Rekrutierung Studie anzeigen

RAFAEL A multicenter open-label phase II trial to evaluate autologous fecal micobiota transfer in combination with first line immune anti-PD-1 and chemotherapy according to investigator's choice for treatment beyond progression in patients with advanced esophageal and gastric adenocarcinoma AIO-STO-0222 · In Vorbereitung Studie anzeigen